Trial Profile

The LATENT Trial: Lytic Activation To Enhance Neoantigen-directed Therapy A Study to Evaluate the Feasibility and Efficacy of the Combined Use of Avelumab With Valproic Acid for the Treatment of Virus-associated Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Valproic acid (Primary)
Indications Anal cancer; Carcinoma; Cervical cancer; Head and neck cancer; Hodgkin's disease; Nasopharyngeal cancer; Non-Hodgkin's lymphoma; Penile cancer; Squamous cell cancer; Vulvovaginal cancer
Focus Therapeutic Use
Acronyms LATENT

26 Jun 2025 Status changed from active, no longer recruiting to completed.
10 Oct 2023 Status changed from recruiting to active, no longer recruiting.
02 Jul 2019 Planned primary completion date changed from 31 Oct 2021 to 30 Mar 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com